O,O'-DIMETHYL ALPHA-(4-CHLORO-2-FLUOROPHENOXYACETOXY)-ALPHA-(FURAN-2-YL)METHYLPHOSPHONATE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	AECHNKXGMALLNK-UHFFFAOYSA-N
Smiles	COP(=O)(OC)C(OC(=O)COc1ccc(Cl)cc1F)c2occc2
InChI	InChI=1S/C15H15ClFO7P/c1-20-25(19,21-2)15(13-4-3-7-22-13)24-14(18)9-23-12-6-5-10(16)8-11(12)17/h3-8,15H,9H2,1-2H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C15H15ClFO7P
Molecular Weight	392.7
AlogP	2.89
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	9.0
Polar Surface Area	94.01
Molecular species	None
Aromatic Rings	2.0
Heavy Atoms	25.0

Assay Description	Organism	Bioactivity
Herbicidal activity against two to three-leaf stage Eclipta prostrata assessed as inhibition of plant growth at 150 g/ha in greenhouse by post-emergence herbicidal activity assay	Eclipta prostrata	70.0 %
Herbicidal activity against 2 to 3 leaf stage Amaranthus retroflexus assessed as inhibition of plant growth at 150 g/ha in greenhouse by postemergence herbicidal activity assay	Amaranthus retroflexus	60.0 %
Herbicidal activity against two to three-leaf stage Brassica rapa subsp. oleifera assessed as inhibition of plant growth at 150 g/ha in greenhouse by postemergence herbicidal activity assay	Brassica rapa subsp. oleifera	75.0 %
Herbicidal activity against two to three-leaf stage Abutilon theophrasti (velvetleaf) assessed as inhibition of plant growth at 150 g/ha in greenhouse by post-emergence herbicidal activity assay	Abutilon theophrasti	70.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2289482
PubChem	71524648

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).